Ecallantide National NME Drug Monograph

Patient reported symptoms by affected location were identified at baseline and scored using the MSCS according to the following scale: 0=normal; 1=mild; 2=moderate; 3=severe. Symptoms were again rated at 4 and 24 hours post initial treatment. The endpoint evaluation was the change from baseline in MSCS score at 4 hours post treatment. ................
................

In order to avoid copyright disputes, this page is only a partial summary.